# Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study

Clinical trial · Cerecin

- Archive id: nct:NCT05809908
- Published: 2023-04-12
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05809908
- Source URL: https://clinicaltrials.gov/study/NCT05809908
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: ALTER-AD
- status: NOT_YET_RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 535
- sponsor: Cerecin
- conditions: Alzheimer Disease
- interventions: DRUG: Tricaprilin; DRUG: Placebo
- start date: 2026-12-01
- start date type: ESTIMATED
- primary completion date: 2029-06-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.